Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 14/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5459933 | 0.91 | HPGD (0.35) | LRRK2KDM4ENPSR1HPGDLMNA | |
| SCHEMBL5439991 | 0.91 | USP30 (0.34) | LRRK2KDM4ENPSR1HPGDLMNA | |
| SCHEMBL5450209 | 0.90 | MAT2A (0.33) | LRRK2 | |
| SCHEMBL5451079 | 0.88 | MAPT (0.32) | KDM4ENPSR1HPGDLMNAPOLB | |
| SCHEMBL5450154 | 0.84 | USP30 (0.34) | KDM4ENPSR1HPGDLMNAPOLB | |
| SCHEMBL5444668 | 0.83 | LMNA (0.33) | LRRK2KDM4EHPGDLMNAMAPT | |
| SCHEMBL5447275 | 0.83 | EGLN2 (0.36) | KDM4ENPSR1HPGDLMNAPOLB | |
| SCHEMBL5447457 | 0.82 | USP30 (0.36) | KDM4EHPGDLMNAMAPTALDH1A1 | |
| SCHEMBL5458301 | 0.80 | GRM5 (0.36) | KDM4ENPSR1HPGDLMNAPOLB | |
| SCHEMBL5442795 | 0.79 | GRM5 (0.35) | KDM4ENPSR1HPGDLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191395-A1 | Heterocyclic compounds having antifungal activity | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1717238-A1 | FUNGICIDAL HETEROCYCLIC COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191395-A1 | Heterocyclic compounds having antifungal activity | ERG28, MANBA, MAN2B1 | LRRK2 2012/4885KDM4E 3019/4885NPSR1 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.